What’s new for 2014?
40+ leading drug formulation experts presenting on cutting-edge bioavailability and solubility strategies
150+ executives from 90+ leading organizations to discuss and hear unique take-home examples, case studies and multiple formulation and preformulation strategies
3 detailed pre-conference workshop sessions
5+ hours of unparalleled networking with the device industries’ most distinguished drug formulation, preformulation and delivery experts over 3 full days including a networking drinks reception
4 Tracked program sessions offering diversity in cutting-edge drug development strategies
Key program sessions include:
Rationale formulation design for poorly soluble compounds
Improving oral bioavailability for poorly water-soluble drug candidates
Solubilization approaches for parenteral routes of administration Enhancing API bioavailability via nanotechnology for drug delivery Improving oral modified release dosage forms
Controlled release / modified release drug delivery
API crystal forms and their bioavailability
Patent-centric formulation approaches
Lipid-based formulations
Optimizing biologics development
Animal models
In-vivo – in-vitro correlation
Dosage strategy
And many more...
Benefit from industry participation from Pfizer, Merck, Novartis, Bristol Myers Squibb, Amgen, GlaxoSmithKline, Roche, Boehringer Ingelheim, Celgene, Eli Lilly, Millennium Pharmaceuticals, Vertex Pharmaceuticals, Genzyme, AstraZeneca, Alcon Labs, and many more drug solubility, bioavailability and delivery experts. Additionally, do not miss keynote, Stephen Byrn (Purdue University) and Chris Benmore (Argonne National Laboratory) discuss innovations in levitation technology for the production of amorphous drugs.
Testimonials:
“Very good examples provided. Great explanations to questions raised!”
- Associate Director, Pharmaceutical Science,Takeda
“A very well organized event!”
- Scientist, DMPK, Lexicon Pharmaceuticals
“By far exceeded expectations! Great floor setup encouraging interaction”
- Product Specialist, Pion, Inc.
Pharma Sources Insight July 2025
